The global Malignant Mesothelioma Therapeutic market is projected to grow from US$ 354.9 million in 2024 to US$ 532.5 million by 2030, at a Compound Annual Growth Rate (CAGR) of 7.0% during the forecast period.

Malignant Mesothelioma Therapeutic Market

Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).

Malignant mesothelioma is a cancer of the thin tissue (mesothelium) that lines the lung, chest wall, and abdomen. The major risk factor for mesothelioma is asbestos exposure.

Market Analysis and Insights: Global Malignant Mesothelioma Therapeutic Market

The classification of Malignant Mesothelioma Therapeutic includes Pemetrexed, Cisplatin and others. The proportion of Pemetrexed in 2019 approaches 50%. Malignant Mesothelioma Therapeutic is mostly used for Pleural Mesothelioma, and the proportion in 2019 is about 80%. Europe is the largest market, with a sales market share above 50% in 2019. Following Europe, Asia Pacific is the second largest sales place with the sales market share of above 1/5. Market competition is intense. Eli Lilly, Teva, Sanofi, Bristol-Myers Squibb, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.

Report Covers:

This report presents an overview of global market for Malignant Mesothelioma Therapeutic market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Malignant Mesothelioma Therapeutic, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Malignant Mesothelioma Therapeutic, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Malignant Mesothelioma Therapeutic revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Malignant Mesothelioma Therapeutic market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Malignant Mesothelioma Therapeutic revenue, projected growth trends, production technology, application and end-user industry.

Market Segmentation

Scope of Malignant Mesothelioma Therapeutic Market Report

Report Metric	Details
Report Name	Malignant Mesothelioma Therapeutic Market
Accounted market size in 2024	US$ 354.9 million
Forecasted market size in 2030	US$ 532.5 million
CAGR	7.0
Base Year	2024
Forecasted years	2024 - 2030
Segment by Type	Pemetrexed Cisplatin Others
Segment by Application	Pleural Mesothelioma Peritoneal Mesothelioma Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Eli Lilly, Teva, Sanofi, Bristol-Myers Squibb, Pfizer, Roche, Merck, Ono Pharmaceutical, Mylan, Fresenius Kabi, Sun Pharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Malignant Mesothelioma Therapeutic in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Malignant Mesothelioma Therapeutic companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Malignant Mesothelioma Therapeutic revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

FAQ for this report

How fast is Malignant Mesothelioma Therapeutic Market growing?

Ans: The Malignant Mesothelioma Therapeutic Market witnessing a CAGR of 7.0 during the forecast period 2024-2030.

What is the Malignant Mesothelioma Therapeutic Market size in 2030?

Ans: The Malignant Mesothelioma Therapeutic Market size in 2030 will be US$ 532.5 million.

What is the Malignant Mesothelioma Therapeutic Market share by type?

Ans: The proportion of Pemetrexed in 2019 approaches 50%.

What is the Malignant Mesothelioma Therapeutic Market share by application?

Ans: Malignant Mesothelioma Therapeutic is mostly used for Pleural Mesothelioma, and the proportion in 2019 is about 80%.

What is the Malignant Mesothelioma Therapeutic Market share by region?

Ans: Europe is the largest market, with a sales market share above 50% in 2019.

Who are the main players in the Malignant Mesothelioma Therapeutic Market report?

Ans: The main players in the Malignant Mesothelioma Therapeutic Market are Eli Lilly, Teva, Sanofi, Bristol-Myers Squibb, Pfizer, Roche, Merck, Ono Pharmaceutical, Mylan, Fresenius Kabi, Sun Pharmaceuticals

What are the Application segmentation covered in the Malignant Mesothelioma Therapeutic Market report?

Ans: The Applications covered in the Malignant Mesothelioma Therapeutic Market report are Pleural Mesothelioma, Peritoneal Mesothelioma, Others

What are the Type segmentation covered in the Malignant Mesothelioma Therapeutic Market report?

Ans: The Types covered in the Malignant Mesothelioma Therapeutic Market report are Pemetrexed, Cisplatin, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Malignant Mesothelioma Therapeutic Market Size Growth Rate by Type, 2019 VS 2023 VS 2030

1.2.2 Pemetrexed

1.2.3 Cisplatin

1.2.4 Others

1.3 Market by Application

1.3.1 Global Malignant Mesothelioma Therapeutic Market Size Growth Rate by Application, 2019 VS 2023 VS 2030

1.3.2 Pleural Mesothelioma

1.3.3 Peritoneal Mesothelioma

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Malignant Mesothelioma Therapeutic Market Perspective (2019-2030)

2.2 Global Malignant Mesothelioma Therapeutic Growth Trends by Region

2.2.1 Malignant Mesothelioma Therapeutic Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Malignant Mesothelioma Therapeutic Historic Market Size by Region (2019-2024)

2.2.3 Malignant Mesothelioma Therapeutic Forecasted Market Size by Region (2025-2030)

2.3 Malignant Mesothelioma Therapeutic Market Dynamics

2.3.1 Malignant Mesothelioma Therapeutic Industry Trends

2.3.2 Malignant Mesothelioma Therapeutic Market Drivers

2.3.3 Malignant Mesothelioma Therapeutic Market Challenges

2.3.4 Malignant Mesothelioma Therapeutic Market Restraints

3 Competition Landscape by Key Players

3.1 Global Revenue Malignant Mesothelioma Therapeutic by Players

3.1.1 Global Malignant Mesothelioma Therapeutic Revenue by Players (2019-2024)

3.1.2 Global Malignant Mesothelioma Therapeutic Revenue Market Share by Players (2019-2024)

3.2 Global Malignant Mesothelioma Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players of Malignant Mesothelioma Therapeutic, Ranking by Revenue, 2022 VS 2023 VS 2024

3.4 Global Malignant Mesothelioma Therapeutic Market Concentration Ratio

3.4.1 Global Malignant Mesothelioma Therapeutic Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Malignant Mesothelioma Therapeutic Revenue in 2023

3.5 Global Key Players of Malignant Mesothelioma Therapeutic Head office and Area Served

3.6 Global Key Players of Malignant Mesothelioma Therapeutic, Product and Application

3.7 Global Key Players of Malignant Mesothelioma Therapeutic, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Malignant Mesothelioma Therapeutic Breakdown Data by Type

4.1 Global Malignant Mesothelioma Therapeutic Historic Market Size by Type (2019-2024)

4.2 Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Type (2025-2030)

5 Malignant Mesothelioma Therapeutic Breakdown Data by Application

5.1 Global Malignant Mesothelioma Therapeutic Historic Market Size by Application (2019-2024)

5.2 Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Malignant Mesothelioma Therapeutic Market Size (2019-2030)

6.2 North America Malignant Mesothelioma Therapeutic Market Size by Type

6.2.1 North America Malignant Mesothelioma Therapeutic Market Size by Type (2019-2024)

6.2.2 North America Malignant Mesothelioma Therapeutic Market Size by Type (2025-2030)

6.2.3 North America Malignant Mesothelioma Therapeutic Market Share by Type (2019-2030)

6.3 North America Malignant Mesothelioma Therapeutic Market Size by Application

6.3.1 North America Malignant Mesothelioma Therapeutic Market Size by Application (2019-2024)

6.3.2 North America Malignant Mesothelioma Therapeutic Market Size by Application (2025-2030)

6.3.3 North America Malignant Mesothelioma Therapeutic Market Share by Application (2019-2030)

6.4 North America Malignant Mesothelioma Therapeutic Market Size by Country

6.4.1 North America Malignant Mesothelioma Therapeutic Market Size by Country: 2019 VS 2023 VS 2030

6.4.2 North America Malignant Mesothelioma Therapeutic Market Size by Country (2019-2024)

6.4.3 North America Malignant Mesothelioma Therapeutic Market Size by Country (2025-2030)

6.4.4 U.S.

6.4.5 Canada

7 Europe

7.1 Europe Malignant Mesothelioma Therapeutic Market Size (2019-2030)

7.2 Europe Malignant Mesothelioma Therapeutic Market Size by Type

7.2.1 Europe Malignant Mesothelioma Therapeutic Market Size by Type (2019-2024)

7.2.2 Europe Malignant Mesothelioma Therapeutic Market Size by Type (2025-2030)

7.2.3 Europe Malignant Mesothelioma Therapeutic Market Share by Type (2019-2030)

7.3 Europe Malignant Mesothelioma Therapeutic Market Size by Application

7.3.1 Europe Malignant Mesothelioma Therapeutic Market Size by Application (2019-2024)

7.3.2 Europe Malignant Mesothelioma Therapeutic Market Size by Application (2025-2030)

7.3.3 Europe Malignant Mesothelioma Therapeutic Market Share by Application (2019-2030)

7.4 Europe Malignant Mesothelioma Therapeutic Market Size by Country

7.4.1 Europe Malignant Mesothelioma Therapeutic Market Size by Country: 2019 VS 2023 VS 2030

7.4.2 Europe Malignant Mesothelioma Therapeutic Market Size by Country (2019-2024)

7.4.3 Europe Malignant Mesothelioma Therapeutic Market Size by Country (2025-2030)

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic Countries

8 China

8.1 China Malignant Mesothelioma Therapeutic Market Size (2019-2030)

8.2 China Malignant Mesothelioma Therapeutic Market Size by Type

8.2.1 China Malignant Mesothelioma Therapeutic Market Size by Type (2019-2024)

8.2.2 China Malignant Mesothelioma Therapeutic Market Size by Type (2025-2030)

8.2.3 China Malignant Mesothelioma Therapeutic Market Share by Type (2019-2030)

8.3 China Malignant Mesothelioma Therapeutic Market Size by Application

8.3.1 China Malignant Mesothelioma Therapeutic Market Size by Application (2019-2024)

8.3.2 China Malignant Mesothelioma Therapeutic Market Size by Application (2025-2030)

8.3.3 China Malignant Mesothelioma Therapeutic Market Share by Application (2019-2030)

9 Asia (excluding China)

9.1 Asia Malignant Mesothelioma Therapeutic Market Size (2019-2030)

9.2 Asia Malignant Mesothelioma Therapeutic Market Size by Type

9.2.1 Asia Malignant Mesothelioma Therapeutic Market Size by Type (2019-2024)

9.2.2 Asia Malignant Mesothelioma Therapeutic Market Size by Type (2025-2030)

9.2.3 Asia Malignant Mesothelioma Therapeutic Market Share by Type (2019-2030)

9.3 Asia Malignant Mesothelioma Therapeutic Market Size by Application

9.3.1 Asia Malignant Mesothelioma Therapeutic Market Size by Application (2019-2024)

9.3.2 Asia Malignant Mesothelioma Therapeutic Market Size by Application (2025-2030)

9.3.3 Asia Malignant Mesothelioma Therapeutic Market Share by Application (2019-2030)

9.4 Asia Malignant Mesothelioma Therapeutic Market Size by Region

9.4.1 Asia Malignant Mesothelioma Therapeutic Market Size by Region: 2019 VS 2023 VS 2030

9.4.2 Asia Malignant Mesothelioma Therapeutic Market Size by Region (2019-2024)

9.4.3 Asia Malignant Mesothelioma Therapeutic Market Size by Region (2025-2030)

9.4.4 Japan

9.4.5 South Korea

9.4.6 China Taiwan

9.4.7 Southeast Asia

9.4.8 India

9.4.9 Australia

10 Middle East, Africa, and Latin America

10.1 Middle East, Africa, and Latin America Malignant Mesothelioma Therapeutic Market Size (2019-2030)

10.2 Middle East, Africa, and Latin America Malignant Mesothelioma Therapeutic Market Size by Type

10.2.1 Middle East, Africa, and Latin America Malignant Mesothelioma Therapeutic Market Size by Type (2019-2024)

10.2.2 Middle East, Africa, and Latin America Malignant Mesothelioma Therapeutic Market Size by Type (2025-2030)

10.2.3 Middle East, Africa, and Latin America Malignant Mesothelioma Therapeutic Market Share by Type (2019-2030)

10.3 Middle East, Africa, and Latin America Malignant Mesothelioma Therapeutic Market Size by Application

10.3.1 Middle East, Africa, and Latin America Malignant Mesothelioma Therapeutic Market Size by Application (2019-2024)

10.3.2 Middle East, Africa, and Latin America Malignant Mesothelioma Therapeutic Market Size by Application (2025-2030)

10.3.3 Middle East, Africa, and Latin America Malignant Mesothelioma Therapeutic Market Share by Application (2019-2030)

10.4 Middle East, Africa, and Latin America Malignant Mesothelioma Therapeutic Market Size by Country

10.4.1 Middle East, Africa, and Latin America Malignant Mesothelioma Therapeutic Market Size by Country: 2019 VS 2023 VS 2030

10.4.2 Middle East, Africa, and Latin America Malignant Mesothelioma Therapeutic Market Size by Country (2019-2024)

10.4.3 Middle East, Africa, and Latin America Malignant Mesothelioma Therapeutic Market Size by Country (2025-2030)

10.4.4 Brazil

10.4.5 Mexico

10.4.6 Turkey

10.4.7 Saudi Arabia

10.4.8 Israel

10.4.9 GCC Countries

11 Key Players Profiles

11.1 Eli Lilly

11.1.1 Eli Lilly Company Details

11.1.2 Eli Lilly Business Overview

11.1.3 Eli Lilly Malignant Mesothelioma Therapeutic Introduction

11.1.4 Eli Lilly Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)

11.1.5 Eli Lilly Recent Developments

11.2 Teva

11.2.1 Teva Company Details

11.2.2 Teva Business Overview

11.2.3 Teva Malignant Mesothelioma Therapeutic Introduction

11.2.4 Teva Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)

11.2.5 Teva Recent Developments

11.3 Sanofi

11.3.1 Sanofi Company Details

11.3.2 Sanofi Business Overview

11.3.3 Sanofi Malignant Mesothelioma Therapeutic Introduction

11.3.4 Sanofi Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)

11.3.5 Sanofi Recent Developments

11.4 Bristol-Myers Squibb

11.4.1 Bristol-Myers Squibb Company Details

11.4.2 Bristol-Myers Squibb Business Overview

11.4.3 Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Introduction

11.4.4 Bristol-Myers Squibb Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)

11.4.5 Bristol-Myers Squibb Recent Developments

11.5 Pfizer

11.5.1 Pfizer Company Details

11.5.2 Pfizer Business Overview

11.5.3 Pfizer Malignant Mesothelioma Therapeutic Introduction

11.5.4 Pfizer Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)

11.5.5 Pfizer Recent Developments

11.6 Roche

11.6.1 Roche Company Details

11.6.2 Roche Business Overview

11.6.3 Roche Malignant Mesothelioma Therapeutic Introduction

11.6.4 Roche Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)

11.6.5 Roche Recent Developments

11.7 Merck

11.7.1 Merck Company Details

11.7.2 Merck Business Overview

11.7.3 Merck Malignant Mesothelioma Therapeutic Introduction

11.7.4 Merck Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)

11.7.5 Merck Recent Developments

11.8 Ono Pharmaceutical

11.8.1 Ono Pharmaceutical Company Details

11.8.2 Ono Pharmaceutical Business Overview

11.8.3 Ono Pharmaceutical Malignant Mesothelioma Therapeutic Introduction

11.8.4 Ono Pharmaceutical Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)

11.8.5 Ono Pharmaceutical Recent Developments

11.9 Mylan

11.9.1 Mylan Company Details

11.9.2 Mylan Business Overview

11.9.3 Mylan Malignant Mesothelioma Therapeutic Introduction

11.9.4 Mylan Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)

11.9.5 Mylan Recent Developments

11.10 Fresenius Kabi

11.10.1 Fresenius Kabi Company Details

11.10.2 Fresenius Kabi Business Overview

11.10.3 Fresenius Kabi Malignant Mesothelioma Therapeutic Introduction

11.10.4 Fresenius Kabi Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)

11.10.5 Fresenius Kabi Recent Developments

11.11 Sun Pharmaceuticals

11.11.1 Sun Pharmaceuticals Company Details

11.11.2 Sun Pharmaceuticals Business Overview

11.11.3 Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Introduction

11.11.4 Sun Pharmaceuticals Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)

11.11.5 Sun Pharmaceuticals Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

List of Tables

Table 1. Global Malignant Mesothelioma Therapeutic Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030

Table 2. Key Players of Pemetrexed

Table 3. Key Players of Cisplatin

Table 4. Key Players of Others

Table 5. Global Malignant Mesothelioma Therapeutic Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030

Table 6. Global Malignant Mesothelioma Therapeutic Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global Malignant Mesothelioma Therapeutic Market Size by Region (2019-2024) & (US$ Million)

Table 8. Global Malignant Mesothelioma Therapeutic Market Share by Region (2019-2024)

Table 9. Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 10. Global Malignant Mesothelioma Therapeutic Market Share by Region (2025-2030)

Table 11. Malignant Mesothelioma Therapeutic Market Trends

Table 12. Malignant Mesothelioma Therapeutic Market Drivers

Table 13. Malignant Mesothelioma Therapeutic Market Challenges

Table 14. Malignant Mesothelioma Therapeutic Market Restraints

Table 15. Global Malignant Mesothelioma Therapeutic Revenue by Players (2019-2024) & (US$ Million)

Table 16. Global Malignant Mesothelioma Therapeutic Revenue Share by Players (2019-2024)

Table 17. Global Top Malignant Mesothelioma Therapeutic by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Malignant Mesothelioma Therapeutic as of 2023)

Table 18. Global Malignant Mesothelioma Therapeutic Industry Ranking 2022 VS 2023 VS 2024

Table 19. Global 5 Largest Players Market Share by Malignant Mesothelioma Therapeutic Revenue (CR5 and HHI) & (2019-2024)

Table 20. Global Key Players of Malignant Mesothelioma Therapeutic, Headquarters and Area Served

Table 21. Global Key Players of Malignant Mesothelioma Therapeutic, Product and Application

Table 22. Global Key Players of Malignant Mesothelioma Therapeutic, Product and Application

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Malignant Mesothelioma Therapeutic Market Size by Type (2019-2024) & (US$ Million)

Table 25. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Type (2019-2024)

Table 26. Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 27. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Type (2025-2030)

Table 28. Global Malignant Mesothelioma Therapeutic Market Size by Application (2019-2024) & (US$ Million)

Table 29. Global Malignant Mesothelioma Therapeutic Revenue Share by Application (2019-2024)

Table 30. Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 31. Global Malignant Mesothelioma Therapeutic Revenue Share by Application (2025-2030)

Table 32. North America Malignant Mesothelioma Therapeutic Market Size by Type (2019-2024) & (US$ Million)

Table 33. North America Malignant Mesothelioma Therapeutic Market Size by Type (2025-2030) & (US$ Million)

Table 34. North America Malignant Mesothelioma Therapeutic Market Size by Application (2019-2024) & (US$ Million)

Table 35. North America Malignant Mesothelioma Therapeutic Market Size by Application (2025-2030) & (US$ Million)

Table 36. North America Malignant Mesothelioma Therapeutic Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 37. North America Malignant Mesothelioma Therapeutic Market Size by Country (2019-2024) & (US$ Million)

Table 38. North America Malignant Mesothelioma Therapeutic Market Size by Country (2025-2030) & (US$ Million)

Table 39. Europe Malignant Mesothelioma Therapeutic Market Size by Type (2019-2024) & (US$ Million)

Table 40. Europe Malignant Mesothelioma Therapeutic Market Size by Type (2025-2030) & (US$ Million)

Table 41. Europe Malignant Mesothelioma Therapeutic Market Size by Application (2019-2024) & (US$ Million)

Table 42. Europe Malignant Mesothelioma Therapeutic Market Size by Application (2025-2030) & (US$ Million)

Table 43. Europe Malignant Mesothelioma Therapeutic Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Europe Malignant Mesothelioma Therapeutic Market Size by Country (2019-2024) & (US$ Million)

Table 45. Europe Malignant Mesothelioma Therapeutic Market Size by Country (2025-2030) & (US$ Million)

Table 46. China Malignant Mesothelioma Therapeutic Market Size by Type (2019-2024) & (US$ Million)

Table 47. China Malignant Mesothelioma Therapeutic Market Size by Type (2025-2030) & (US$ Million)

Table 48. China Malignant Mesothelioma Therapeutic Market Size by Application (2019-2024) & (US$ Million)

Table 49. China Malignant Mesothelioma Therapeutic Market Size by Application (2025-2030) & (US$ Million)

Table 50. Asia Malignant Mesothelioma Therapeutic Market Size by Type (2019-2024) & (US$ Million)

Table 51. Asia Malignant Mesothelioma Therapeutic Market Size by Type (2025-2030) & (US$ Million)

Table 52. Asia Malignant Mesothelioma Therapeutic Market Size by Application (2019-2024) & (US$ Million)

Table 53. Asia Malignant Mesothelioma Therapeutic Market Size by Application (2025-2030) & (US$ Million)

Table 54. Asia Malignant Mesothelioma Therapeutic Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030

Table 55. Asia Malignant Mesothelioma Therapeutic Market Size by Region (2019-2024) & (US$ Million)

Table 56. Asia Malignant Mesothelioma Therapeutic Market Size by Region (2025-2030) & (US$ Million)

Table 57. Middle East, Africa, and Latin America Malignant Mesothelioma Therapeutic Market Size by Type (2019-2024) & (US$ Million)

Table 58. Middle East, Africa, and Latin America Malignant Mesothelioma Therapeutic Market Size by Type (2025-2030) & (US$ Million)

Table 59. Middle East, Africa, and Latin America Malignant Mesothelioma Therapeutic Market Size by Application (2019-2024) & (US$ Million)

Table 60. Middle East, Africa, and Latin America Malignant Mesothelioma Therapeutic Market Size by Application (2025-2030) & (US$ Million)

Table 61. Middle East, Africa, and Latin America Malignant Mesothelioma Therapeutic Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 62. Middle East, Africa, and Latin America Malignant Mesothelioma Therapeutic Market Size by Country (2019-2024) & (US$ Million)

Table 63. Middle East, Africa, and Latin America Malignant Mesothelioma Therapeutic Market Size by Country (2025-2030) & (US$ Million)

Table 64. Eli Lilly Company Details

Table 65. Eli Lilly Business Overview

Table 66. Eli Lilly Malignant Mesothelioma Therapeutic Product

Table 67. Eli Lilly Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)

Table 68. Eli Lilly Recent Developments

Table 69. Teva Company Details

Table 70. Teva Business Overview

Table 71. Teva Malignant Mesothelioma Therapeutic Product

Table 72. Teva Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)

Table 73. Teva Recent Developments

Table 74. Sanofi Company Details

Table 75. Sanofi Business Overview

Table 76. Sanofi Malignant Mesothelioma Therapeutic Product

Table 77. Sanofi Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)

Table 78. Sanofi Recent Developments

Table 79. Bristol-Myers Squibb Company Details

Table 80. Bristol-Myers Squibb Business Overview

Table 81. Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Product

Table 82. Bristol-Myers Squibb Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)

Table 83. Bristol-Myers Squibb Recent Developments

Table 84. Pfizer Company Details

Table 85. Pfizer Business Overview

Table 86. Pfizer Malignant Mesothelioma Therapeutic Product

Table 87. Pfizer Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)

Table 88. Pfizer Recent Developments

Table 89. Roche Company Details

Table 90. Roche Business Overview

Table 91. Roche Malignant Mesothelioma Therapeutic Product

Table 92. Roche Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)

Table 93. Roche Recent Developments

Table 94. Merck Company Details

Table 95. Merck Business Overview

Table 96. Merck Malignant Mesothelioma Therapeutic Product

Table 97. Merck Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)

Table 98. Merck Recent Developments

Table 99. Ono Pharmaceutical Company Details

Table 100. Ono Pharmaceutical Business Overview

Table 101. Ono Pharmaceutical Malignant Mesothelioma Therapeutic Product

Table 102. Ono Pharmaceutical Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)

Table 103. Ono Pharmaceutical Recent Developments

Table 104. Mylan Company Details

Table 105. Mylan Business Overview

Table 106. Mylan Malignant Mesothelioma Therapeutic Product

Table 107. Mylan Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)

Table 108. Mylan Recent Developments

Table 109. Fresenius Kabi Company Details

Table 110. Fresenius Kabi Business Overview

Table 111. Fresenius Kabi Malignant Mesothelioma Therapeutic Product

Table 112. Fresenius Kabi Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)

Table 113. Fresenius Kabi Recent Developments

Table 114. Sun Pharmaceuticals Company Details

Table 115. Sun Pharmaceuticals Business Overview

Table 116. Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Product

Table 117. Sun Pharmaceuticals Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024) & (US$ Million)

Table 118. Sun Pharmaceuticals Recent Developments

Table 119. Research Programs/Design for This Report

Table 120. Key Data Information from Secondary Sources

Table 121. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Malignant Mesothelioma Therapeutic Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)

Figure 2. Global Malignant Mesothelioma Therapeutic Market Share by Type: 2023 VS 2030

Figure 3. Pemetrexed Features

Figure 4. Cisplatin Features

Figure 5. Others Features

Figure 6. Global Malignant Mesothelioma Therapeutic Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)

Figure 7. Global Malignant Mesothelioma Therapeutic Market Share by Application: 2023 VS 2030

Figure 8. Pleural Mesothelioma Case Studies

Figure 9. Peritoneal Mesothelioma Case Studies

Figure 10. Others Case Studies

Figure 11. Malignant Mesothelioma Therapeutic Report Years Considered

Figure 12. Global Malignant Mesothelioma Therapeutic Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 13. Global Malignant Mesothelioma Therapeutic Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 14. Global Malignant Mesothelioma Therapeutic Market Share by Region: 2023 VS 2030

Figure 15. Global Malignant Mesothelioma Therapeutic Market Share by Players in 2023

Figure 16. Global Top Malignant Mesothelioma Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Malignant Mesothelioma Therapeutic as of 2023)

Figure 17. The Top 10 and 5 Players Market Share by Malignant Mesothelioma Therapeutic Revenue in 2023

Figure 18. North America Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 19. North America Malignant Mesothelioma Therapeutic Market Share by Type (2019-2030)

Figure 20. North America Malignant Mesothelioma Therapeutic Market Share by Application (2019-2030)

Figure 21. North America Malignant Mesothelioma Therapeutic Market Share by Country (2019-2030)

Figure 22. United States Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Canada Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Europe Malignant Mesothelioma Therapeutic Market Size YoY (2019-2030) & (US$ Million)

Figure 25. Europe Malignant Mesothelioma Therapeutic Market Share by Type (2019-2030)

Figure 26. Europe Malignant Mesothelioma Therapeutic Market Share by Application (2019-2030)

Figure 27. Europe Malignant Mesothelioma Therapeutic Market Share by Country (2019-2030)

Figure 28. Germany Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. France Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. U.K. Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Italy Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Russia Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Nordic Countries Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. China Malignant Mesothelioma Therapeutic Market Size YoY (2019-2030) & (US$ Million)

Figure 35. China Malignant Mesothelioma Therapeutic Market Share by Type (2019-2030)

Figure 36. China Malignant Mesothelioma Therapeutic Market Share by Application (2019-2030)

Figure 37. Asia Malignant Mesothelioma Therapeutic Market Size YoY (2019-2030) & (US$ Million)

Figure 38. Asia Malignant Mesothelioma Therapeutic Market Share by Type (2019-2030)

Figure 39. Asia Malignant Mesothelioma Therapeutic Market Share by Application (2019-2030)

Figure 40. Asia Malignant Mesothelioma Therapeutic Market Share by Region (2019-2030)

Figure 41. Japan Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. South Korea Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. China Taiwan Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Southeast Asia Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. India Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Australia Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Middle East, Africa, and Latin America Malignant Mesothelioma Therapeutic Market Size YoY (2019-2030) & (US$ Million)

Figure 48. Middle East, Africa, and Latin America Malignant Mesothelioma Therapeutic Market Share by Type (2019-2030)

Figure 49. Middle East, Africa, and Latin America Malignant Mesothelioma Therapeutic Market Share by Application (2019-2030)

Figure 50. Middle East, Africa, and Latin America Malignant Mesothelioma Therapeutic Market Share by Country (2019-2030)

Figure 51. Brazil Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 52. Mexico Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 53. Turkey Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 54. Saudi Arabia Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 55. Israel Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 56. GCC Countries Malignant Mesothelioma Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 57. Eli Lilly Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)

Figure 58. Teva Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)

Figure 59. Sanofi Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)

Figure 60. Bristol-Myers Squibb Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)

Figure 61. Pfizer Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)

Figure 62. Roche Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)

Figure 63. Merck Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)

Figure 64. Ono Pharmaceutical Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)

Figure 65. Mylan Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)

Figure 66. Fresenius Kabi Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)

Figure 67. Sun Pharmaceuticals Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2019-2024)

Figure 68. Bottom-up and Top-down Approaches for This Report

Figure 69. Data Triangulation

Figure 70. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-39R14639

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Cancer Early Detection and Diagnosis - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-37I14671

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Global One-Stop Radiotherapy Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-33G18542

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Immunotherapy for Neuroblastoma - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-1A14903

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Malignant Mesothelioma Therapeutic Market Insights, Forecast to 2030

Published Date: August 2024

Report Code: QYRE-Auto-13B13087

Global Malignant Mesothelioma Therapeutic Market Insights, Forecast to 2030

FEATURED COMPANIES

Malignant Mesothelioma Therapeutic Market Size

Malignant Mesothelioma Therapeutic Market

Scope of Malignant Mesothelioma Therapeutic Market Report

Chapter Outline

FAQ for this report

How fast is Malignant Mesothelioma Therapeutic Market growing?

What is the Malignant Mesothelioma Therapeutic Market size in 2030?

What is the Malignant Mesothelioma Therapeutic Market share by type?

What is the Malignant Mesothelioma Therapeutic Market share by application?

What is the Malignant Mesothelioma Therapeutic Market share by region?

Who are the main players in the Malignant Mesothelioma Therapeutic Market report?

What are the Application segmentation covered in the Malignant Mesothelioma Therapeutic Market report?

What are the Type segmentation covered in the Malignant Mesothelioma Therapeutic Market report?

FEATURED COMPANIES

RELATED REPORTS